<?xml version="1.0" encoding="UTF-8"?>
<p id="par0010">Despite 50 years of vaccine research none is yet licensed for the prevention of RSV infection or disease. There are currently over fifty vaccines in different stages of development: many with the aim of prevention of early infant RSV disease. While the most advanced (in phase III trials) is a maternal vaccine to boost transplacental antibody transfer (
 <xref rid="bib0140" ref-type="bibr">Nigel Thomas (2017)</xref>; â€œ
 <xref rid="bib0175" ref-type="bibr">RSV Vaccine Snapshot (2016)</xref>; 
 <xref rid="bib0215" ref-type="bibr">WHO (2016)</xref>, a variety of product types and range of strategies for protecting young children are under investigation including indirect protection by targeting older infants, elder siblings and family cocooning (
 <xref rid="bib0020" ref-type="bibr">Anderson et al., 2013</xref>; 
 <xref rid="bib0080" ref-type="bibr">Kinyanjui et al., 2015</xref>; 
 <xref rid="bib0150" ref-type="bibr">Poletti et al., 2015</xref>).
</p>
